In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.   

• Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17
• Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45
• Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04
• Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04
• Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16
• John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18
• Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13
• Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01
• Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30
• Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43
• Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00
• Thanks for listening 18:45

Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.